top of page

Latest News

30.10.25

Autumn updates: What’s ahead for CERTAINTY

Preparing for the upcoming stakeholder workshop, key deliverables, and strategic coordination activities

Autumn updates: What’s ahead for CERTAINTY

30.9.25

CERTAINTY holds first EC monitoring meeting

Positive feedback highlights strong progress in building a virtual twin for personalised CAR T cell therapy

CERTAINTY holds first EC monitoring meeting

15.8.25

Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies

CERTAINTY consortium outlines blueprint for next-generation digital health tools to support CAR T cell therapy

Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies

22.7.25

Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma

New CERTAINTY-supported publication identifies spleen size as a prognostic marker in CAR T cell treatment

Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma

8.7.25

HZDR joins the CERTAINTY consortium

A seamless transition of expertise ensures continued progress in stakeholder engagement and socio-economic research

HZDR joins the CERTAINTY consortium
Key visuals (2).png

© Artur - stock.adobe.com / Fraunhofer IZI

For further information on the CERTAINTY project, feel free to contact us through email or keep up with our latest updates by following our social media channels.  

 

Email: info@certainty-virtualtwin.eu

Funded by the European Union Logo

This project was funded by the European Union under Grant Agreement number 101136379. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.

© 2025 by Collaborate Project Management GmbH.

  • LinkedIn
  • Youtube
bottom of page